What is PolyActiva?
PolyActiva specializes in advanced biodegradable implants designed for sustained drug delivery, aiming to improve patient outcomes for ophthalmic conditions such as glaucoma. Their proprietary Prezia Sustained Drug Delivery Technology platform is built on robust scientific research, enabling precise and controlled medication release. The company's focus on enhancing the quality of life for patients through effective long-term treatment options positions it as a key player in the medical technology sector.
How much funding has PolyActiva raised?
PolyActiva has raised a total of $36.9M across 3 funding rounds:
Series A
$1.6M
Series B
$9.5M
Series C
$25.8M
Series A (2011): $1.6M, investors not publicly disclosed
Series B (2013): $9.5M led by Medical Research Commercialisation Fund (MRCF)
Series C (2025): $25.8M supported by NRFC and Brandon Capital
Key Investors in PolyActiva
NRFC
The National Reconstruction Fund Corporation (NRFC) is an Australian Government initiative focused on diversifying and transforming the nation's industry and economy through strategic investments in priority sectors, including medical science. It provides finance for high-value projects to enhance Australian companies' capabilities and resilience.
Brandon Capital
Brandon Capital Partners is a venture capital firm specializing in seed and venture capital investments within the biomedical sector, supporting life science companies dedicated to improving patient outcomes through innovative medical technologies.
Medical Research Commercialisation Fund (MRCF)
The Medical Research Commercialisation Fund (MRCF), operating under Brandon BioCatalyst, is a leading life science investment fund in Australia and New Zealand, focused on transforming biomedical research into life-saving medical products and collaborating with research institutes and superannuation funds.
What's next for PolyActiva?
The recent substantial capital infusion, characterized as a major strategic investment, signals PolyActiva's transition into a scaling phase. This financing is expected to accelerate the commercialization of their Prezia technology and potentially fund further clinical trials or market expansion. The company's trajectory suggests a strong focus on leveraging its Phase 2 clinical data to secure broader market adoption and partnerships, solidifying its position in the competitive ophthalmic drug delivery market.
See full PolyActiva company page
